IRIS UniCatt

Baldin, Gianmaria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 678
EU - Europa 497
AS - Asia 320
SA - Sud America 84
AF - Africa 6
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 1.587
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 665
SE - Svezia 141
CN - Cina 126
IT - Italia 104
SG - Singapore 99
FR - Francia 74
BR - Brasile 72
DE - Germania 64
IN - India 32
IE - Irlanda 28
ID - Indonesia 23
FI - Finlandia 19
RU - Federazione Russa 13
GB - Regno Unito 12
KR - Corea 11
PL - Polonia 10
CA - Canada 9
AT - Austria 7
AR - Argentina 6
UA - Ucraina 6
BE - Belgio 5
TR - Turchia 5
HK - Hong Kong 4
ES - Italia 3
JP - Giappone 3
AE - Emirati Arabi Uniti 2
CI - Costa d'Avorio 2
CL - Cile 2
CO - Colombia 2
IR - Iran 2
LV - Lettonia 2
MX - Messico 2
NL - Olanda 2
NO - Norvegia 2
OM - Oman 2
TW - Taiwan 2
ZA - Sudafrica 2
BD - Bangladesh 1
BG - Bulgaria 1
BO - Bolivia 1
CH - Svizzera 1
DZ - Algeria 1
EC - Ecuador 1
ET - Etiopia 1
EU - Europa 1
GR - Grecia 1
IQ - Iraq 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LT - Lituania 1
MO - Macao, regione amministrativa speciale della Cina 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
TH - Thailandia 1
UZ - Uzbekistan 1
VN - Vietnam 1
Totale 1.587
Salva come PNG Salva come JPEG
Città #
Chandler 189
Singapore 72
Ashburn 65
New York 42
Dublin 28
Rome 28
Redmond 25
San Mateo 25
Jakarta 23
Nanjing 22
Milan 18
Boston 17
Cattolica 16
Hefei 16
Dearborn 15
Princeton 15
Redwood City 15
Helsinki 14
Wilmington 14
Marseille 10
Seoul 10
Jacksonville 9
The Dalles 9
Frankfurt am Main 8
Beijing 7
Changsha 7
Moscow 6
Shenyang 6
Toronto 6
Belo Horizonte 5
Brussels 5
Los Angeles 5
Düsseldorf 4
Guangzhou 4
Jiaxing 4
Kraków 4
Lauterbourg 4
Munich 4
Nanchang 4
Santa Clara 4
São Paulo 4
Tianjin 4
Vienna 4
Washington 4
Alcalá de Henares 3
Augusta 3
Fairfield 3
Hong Kong 3
Jinan 3
Lawrence 3
Mountain View 3
Ottawa 3
Portland 3
Seattle 3
Tokyo 3
Warsaw 3
Abidjan 2
Ankara 2
Ann Arbor 2
Bexley 2
Brasília 2
Buenos Aires 2
Campinas 2
Chengdu 2
Chicago 2
Chongqing 2
Falkenstein 2
Fuzhou 2
Guarulhos 2
Hebei 2
Leawood 2
London 2
Muscat 2
Norwalk 2
Oslo 2
Palermo 2
Paris 2
Pune 2
Riga 2
Roubaix 2
Shanghai 2
Wuhan 2
Agudos 1
Andover 1
Andrelândia 1
Ardabil 1
Atlanta 1
Baltimore 1
Bangalore 1
Barcarena 1
Barreiros 1
Belford Roxo 1
Belém 1
Bento Fernandes 1
Boardman 1
Bogotá 1
Brasilândia de Minas 1
Brooklyn 1
Cambridge 1
Camden 1
Totale 906
Salva come PNG Salva come JPEG
Nome #
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 116
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 94
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 88
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 87
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 86
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice 84
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy 80
Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure 80
Efficacy and safety of raltegravir in switch strategies in virologically suppressed patients: long-term data from clinical practice 77
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 75
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication 73
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: A retrospective study from the clinical practice 73
Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016 73
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study 68
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 65
Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors, non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: a multicenter retrospective cohort study 63
Predictors of choice of initial antifungal treatment in intraabdominal candidiasis 61
HIV and vicarious stigma in a cohort of people living with HIV in Italy: What happens when the stigma is fueled by healthcare providers? 53
Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice 50
Differences in the Long-term Impact of the COVID-19 Pandemic on the Mental Health and Professional Quality of Life of Resident and Specialist Physicians 40
Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed 38
Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV 26
Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice 25
Autochthonous dengue outbreak in Rome, Italy, in 2023 24
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: A real life multicentre cohort 13
Real World Data from an Italian Outpatient Clinical Setting and from Home Care Assistance of Treatment-Experienced PWH Switching to CAB + RPV Regimen: A Prospective Observational Study 7
Necrotizing mpox with persistent microbiological positivity despite the use of tecovirimat: A case report 7
Assessing dengue seroprevalence among people living with HIV (PLWH) in rome, Italy: Insights from the 2023 Italian autochthonous outbreak 7
Totale 1.633
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.218
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.218
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202045 0 0 0 0 0 0 0 0 0 0 43 2
2020/202168 6 2 3 0 9 5 2 1 4 13 17 6
2021/2022155 4 0 4 24 5 6 0 27 3 15 25 42
2022/2023438 63 65 38 61 24 46 25 40 54 1 11 10
2023/2024221 13 40 4 20 4 79 6 6 1 8 21 19
2024/2025457 13 8 46 28 46 28 45 19 46 41 137 0
Totale 1.633